AcelRx Pharmaceuticals (ACRX) Posts Q3 Loss of 30c/Share
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Join SI Premium – FREE
AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $408 thousand versus the consensus estimate of $80 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
- Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
